In this study, we conducted a series of pooled analyses to clarify the survival benefit in the subgroup of different PD-L1 expression patients with gastric adenocarcinoma, and further assessed the probably optimal cutoff value of PD-L1 CPS that patients could significantly benefit from adding ICIs treatment to chemotherapy, stratified by Asian and global patients. The gene discussed is CD274; the disease is gastric adenocarcinoma.